175 related articles for article (PubMed ID: 11961667)
61. Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer.
Shirakawa T; Gotoh A; Zhang Z; Kao C; Chung LW; Gardner TA
Urology; 2004 Mar; 63(3):613-8. PubMed ID: 15028478
[TBL] [Abstract][Full Text] [Related]
62. Prostate, adrenocortical, and brown adipose tumors in fetal globin/T antigen transgenic mice.
Perez-Stable C; Altman NH; Brown J; Harbison M; Cray C; Roos BA
Lab Invest; 1996 Feb; 74(2):363-73. PubMed ID: 8780156
[TBL] [Abstract][Full Text] [Related]
63. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
[TBL] [Abstract][Full Text] [Related]
64. Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers.
Lillehammer T; Tveito S; Engesaeter BO; Fodstad O; Maelandsmo GM; Engebraaten O
Cancer Gene Ther; 2005 Nov; 12(11):864-72. PubMed ID: 15891771
[TBL] [Abstract][Full Text] [Related]
65. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer.
Freytag SO; Khil M; Stricker H; Peabody J; Menon M; DePeralta-Venturina M; Nafziger D; Pegg J; Paielli D; Brown S; Barton K; Lu M; Aguilar-Cordova E; Kim JH
Cancer Res; 2002 Sep; 62(17):4968-76. PubMed ID: 12208748
[TBL] [Abstract][Full Text] [Related]
66. ATRA enhances bystander effect of suicide gene therapy in the treatment of prostate cancer.
Chen W; Yan C; Hou J; Pu J; Ouyang J; Wen D
Urol Oncol; 2008; 26(4):397-405. PubMed ID: 18367126
[TBL] [Abstract][Full Text] [Related]
67. Rap2 regulates androgen sensitivity in human prostate cancer cells.
Bigler D; Gioeli D; Conaway MR; Weber MJ; Theodorescu D
Prostate; 2007 Oct; 67(14):1590-9. PubMed ID: 17918750
[TBL] [Abstract][Full Text] [Related]
68. Ovarian cancer G protein-coupled receptor 1, a new metastasis suppressor gene in prostate cancer.
Singh LS; Berk M; Oates R; Zhao Z; Tan H; Jiang Y; Zhou A; Kirmani K; Steinmetz R; Lindner D; Xu Y
J Natl Cancer Inst; 2007 Sep; 99(17):1313-27. PubMed ID: 17728215
[TBL] [Abstract][Full Text] [Related]
69. Epstein-Barr virus-based vector improves the tumor cell killing effect of pituitary tumor in HVJ-liposome-mediated transcriptional targeting suicide gene therapy.
Izumo T; Ohtsuru A; Tokunaga Y; Namba H; Kaneda Y; Nagata I; Yamashita S
Int J Oncol; 2007 Aug; 31(2):379-87. PubMed ID: 17611695
[TBL] [Abstract][Full Text] [Related]
70. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.
Rodriguez R; Schuur ER; Lim HY; Henderson GA; Simons JW; Henderson DR
Cancer Res; 1997 Jul; 57(13):2559-63. PubMed ID: 9205053
[TBL] [Abstract][Full Text] [Related]
71. Schedule-dependence of C-CAM1 adenovirus gene therapy in a prostate cancer model.
Lin SH; Pu YS; Luo W; Wang Y; Logothetis CJ
Anticancer Res; 1999; 19(1A):337-40. PubMed ID: 10226564
[TBL] [Abstract][Full Text] [Related]
72. Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease.
Martiniello-Wilks R; Dane A; Voeks DJ; Jeyakumar G; Mortensen E; Shaw JM; Wang XY; Both GW; Russell PJ
J Gene Med; 2004 Jan; 6(1):43-54. PubMed ID: 14716676
[TBL] [Abstract][Full Text] [Related]
73. Adenovirus-mediated interferon-beta gene therapy suppresses growth and metastasis of human prostate cancer in nude mice.
Cao G; Su J; Lu W; Zhang F; Zhao G; Marteralli D; Dong Z
Cancer Gene Ther; 2001 Jul; 8(7):497-505. PubMed ID: 11498771
[TBL] [Abstract][Full Text] [Related]
74. Sensitization of prostate cancer cell lines to 5-fluorocytosine induced by adenoviral vector carrying a CD transcription unit.
Yin L; Fu S; Wang X; Nanakorn T; Won J; Deisseroth A
Chin Med J (Engl); 2001 Sep; 114(9):972-5. PubMed ID: 11780394
[TBL] [Abstract][Full Text] [Related]
75. Conditionally replicating adenovirus therapy utilizing bone sialoprotein promoter (Ad-BSP-E1a) in an in vivo study of treating androgen-independent intraosseous prostate cancer.
Li Y; Kacka M; Thompson M; Hsieh JT; Koeneman KS
Urol Oncol; 2011; 29(6):624-33. PubMed ID: 19963408
[TBL] [Abstract][Full Text] [Related]
76. Tumor-suppressive activity of CD66a in prostate cancer.
Luo W; Tapolsky M; Earley K; Wood CG; Wilson DR; Logothetis CJ; Lin SH
Cancer Gene Ther; 1999; 6(4):313-21. PubMed ID: 10419049
[TBL] [Abstract][Full Text] [Related]
77. Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study.
Kleinerman DI; Zhang WW; Lin SH; Nguyen TV; von Eschenbach AC; Hsieh JT
Cancer Res; 1995 Jul; 55(13):2831-6. PubMed ID: 7796410
[TBL] [Abstract][Full Text] [Related]
78. Creation of a new transgene cloning site near the right ITR of Ad5 results in reduced enhancer interference with tissue-specific and regulatable promoters.
Rubinchik S; Lowe S; Jia Z; Norris J; Dong J
Gene Ther; 2001 Feb; 8(3):247-53. PubMed ID: 11313797
[TBL] [Abstract][Full Text] [Related]
79. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy.
Okegawa T; Li Y; Pong RC; Bergelson JM; Zhou J; Hsieh JT
Cancer Res; 2000 Sep; 60(18):5031-6. PubMed ID: 11016624
[TBL] [Abstract][Full Text] [Related]
80. Targeting and eradicating cancer cells by a prostate-specific vector carrying the diphtheria toxin A gene.
Pang S
Cancer Gene Ther; 2000 Jul; 7(7):991-6. PubMed ID: 10917201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
